Law Firm Probes InMed Deal as Shareholders Face Dilution in Mentari Merger

Brodsky & Smith, a nationally recognized shareholder rights law firm, has launched a formal investigation into potential breaches of fiduciary duty by the Board of Directors at InMed Pharmaceuticals Inc. ($INM) concerning the company's proposed acquisition by Mentari Therapeutics. The investigation centers on whether the board adequately fulfilled its obligations to shareholders by conducting a fair and thorough sales process and securing equitable deal terms, particularly given the substantial shareholder dilution embedded in the transaction structure.

The move underscores growing scrutiny over InMed's sale, where the company's shareholders are projected to own merely 1.51% of the combined entity following the merger's completion. This minimal equity stake has triggered investor concern that the deal undervalues InMed's assets and future prospects, raising fundamental questions about whether board members acted in shareholders' best interests or allowed themselves to be influenced by other considerations.

Key Details of the Investigation

Brodsky & Smith is examining several critical aspects of the transaction:

• Shareholder dilution: InMed shareholders receiving only approximately 1.51% ownership in the merged company
• Board process fairness: Whether directors conducted adequate due diligence and solicited competing bids
• Valuation concerns: Whether the consideration offered reflects true fair value for InMed's operations and intellectual property
• Disclosure adequacy: The completeness and accuracy of information provided to shareholders regarding deal rationale and alternatives considered

The investigation represents a formal response to investor concerns that have emerged around the acquisition announcement. Shareholder litigation related to merger transactions has become increasingly common in recent years, with legal firms routinely challenging deal structures that appear to disadvantage equity holders. The 1.51% stake that InMed shareholders will retain is particularly noteworthy—it suggests a transaction structure where Mentari Therapeutics or its backers are acquiring InMed at a valuation that heavily favors the acquirer.

Investors holding $INM shares during the relevant period may be eligible to participate in the investigation or any subsequent legal action, making this development material for current shareholders and those considering positions in the stock.

Market Context and Industry Backdrop

InMed Pharmaceuticals operates in the highly competitive and regulated biopharmaceutical sector, where merger and acquisition activity remains robust despite macroeconomic headwinds. The pharmaceutical and biotech industries have witnessed significant consolidation over the past decade, driven by larger companies seeking to expand pipelines, acquire promising drug candidates, or gain access to emerging technologies.

The 1.51% ownership stake that InMed shareholders will retain suggests a transaction structure typical of acquisitions where:

• A larger or better-capitalized acquirer absorbs a smaller biotech company
• Deal consideration may consist primarily of cash, debt assumption, or equity in the combined entity weighted heavily toward the buyer
• Shareholders of the acquired company experience substantial dilution relative to their pre-transaction ownership percentage

These dynamics are not uncommon in biotech M&A, but they frequently trigger shareholder litigation when equity holders believe the process was compromised or valuations inadequate. The Brodsky & Smith investigation signals that market participants believe potential irregularities warrant formal legal scrutiny.

The broader context matters here: biotech shareholders have become increasingly sophisticated in challenging transactions they view as unfavorable. Institutional investors and retail shareholders alike are more willing to engage counsel when deal structures raise red flags about board independence, process rigor, or valuation methodology.

Investor Implications and Future Outlook

For InMed shareholders, the Brodsky & Smith investigation carries several important implications:

Near-term impacts:

• Potential delays to deal closure if legal challenges mount
• Continued scrutiny of board disclosures and process documentation
• Possible modifications to deal terms if fiduciary duty violations are substantiated
• Share price volatility as litigation risk factors into investor calculations

Strategic considerations:

• If the investigation uncovers genuine process failures, shareholders may have grounds for damages or renegotiated terms
• A successful challenge could force the board to restart the sales process or explore alternative transactions
• Reputational consequences for board members and company management

For the broader pharmaceutical and biotech sectors, this investigation adds to mounting pressure on boards to demonstrate robust M&A governance. Institutional investors are increasingly scrutinizing deal processes, demanding fairness opinions from independent advisors, and ensuring proper disclosure of strategic alternatives. Directors and officers are facing heightened liability exposure, which some argue is driving more equitable transaction outcomes but others contend may discourage beneficial acquisitions.

The investigation also serves as a reminder that transaction announcements in biotech frequently prompt legal review. Shareholders considering buying or holding $INM shares during the merger pendency should account for litigation risk, including the possibility that a successful challenge could extend the timeline or materially alter deal economics.

InMed shareholders and potential acquirers should monitor court filings and regulatory developments closely. The investigation's trajectory will likely influence how institutional investors view the transaction's ultimate viability and whether alternative bids might emerge if the current deal faces sustained legal headwinds.

The Brodsky & Smith investigation represents a critical juncture for InMed shareholders, highlighting the importance of vigilant board oversight and transparent M&A processes in an era of heightened investor activism and legal scrutiny.